Journal
Blood Advances
Publication Date
9-8-2026
Volume
10
Issue
17
First Page
5778
Last Page
5788
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2026020123
Rights and Permissions
McGuirk JP, Ghobadi A, Bachier CR, Shaughnessy PJ, Awan F, Maakaron JE, Bishop MR, Ho PJ, Tam CS, Dickinson M, Darrah JM, Waller EK, Murthy HS, Ross A, Williams LM, Pan C, Stevens WN, Serwer L, Nguyen T, Terrett J, Kalaitzidis D, Ma A, Xu H, Benton M, Weaver A, Cohen SB, Maziarz RT, Cheah C. Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026 Sep 8;10(17):5778-5788. doi: 10.1182/bloodadvances.2026020123. © 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
McGuirk, Joseph P; Ghobadi, Armin; and et al., "Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma." Blood Advances. 10, 17. 5778 - 5788. (2026).
https://digitalcommons.wustl.edu/oa_4/7459
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
